Mode
Text Size
Log in / Sign up

Women with Polycystic Ovary Syndrome have 24% prevalence of Gestational Diabetes MellitusWomen with Polycystic Ovary Syndrome face higher risk of gestational diabetes

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Recognize that women with PCOS have a high risk of Gestational Diabetes Mellitus, with an observed prevalence of 24%.

This systematic review and meta-analysis evaluates the prevalence of Gestational Diabetes Mellitus (GDM) among women with Polycystic Ovary Syndrome (PCOS). The analysis included data from 5,507 women to establish a baseline for GDM risk in this specific population.

The primary finding is an overall GDM prevalence of 24% (95% CI: 20%-28%) among the PCOS cohort. Subgroup analyses showed a 21.7% prevalence in cohort studies, 26.0% when using one-step diagnostic criteria, and 18.7% when using two-step diagnostic criteria. Several factors were associated with GDM: HOMA-IR (OR = 3.41), family history of diabetes (OR = 2.88), gestational weight gain (OR = 1.58), and pre-pregnancy BMI (OR = 1.39).

The authors note significant limitations, including substantial heterogeneity (I^2 = 89.9%) and a wide prediction interval (10%-46%). Because the data are observational, these findings indicate an association rather than a causal link. Clinicians may consider PCOS patients as a high-risk group for GDM, suggesting that early monitoring of glucose metabolism and weight management may be beneficial for this population.

How this fits prior evidence

This meta-analysis addresses a gap in quantifying the specific prevalence of Gestational Diabetes Mellitus among women with Polycystic Ovary Syndrome. It complements existing evidence regarding PCOS management, such as the use of GLP-1 receptor agonists and metformin for weight reduction, by identifying GDM as a significant risk factor in this population. While previous findings noted an inverse correlation between serum 25(OH)D and insulin resistance in women with PCOS, this study provides specific prevalence data (24%) for GDM in the same cohort.

Managing a pregnancy can be stressful, especially when dealing with underlying health conditions. For women with Polycystic Ovary Syndrome (PCOS), there is an added layer of concern: the risk of developing gestational diabetes, which is high blood sugar that develops during pregnancy.

A large review of data from over 5,500 women found that about 24% of those with PCOS developed gestational diabetes. Several factors were linked to this higher risk, including a higher body mass index (BMI) before pregnancy, more weight gain during pregnancy, and having a family history of diabetes. One specific measure of insulin resistance, called HOMA-IR, also showed a strong link to the condition.

While these findings show that women with PCOS are at high risk, it is important to remember this data comes from observational studies rather than clinical trials. Because the results varied widely across different studies, the exact range of risk can be broad. These findings suggest that early monitoring and weight management may be helpful for those managing both PCOS and a pregnancy.

What this means for you:
Women with Polycystic Ovary Syndrome have a higher risk of gestational diabetes, especially if they have certain risk factors.

Common questions

How common is gestational diabetes in women with PCOS?

The study found that approximately 24% of women with Polycystic Ovary Syndrome (PCOS) developed gestational diabetes. This number can vary depending on the diagnostic method used, ranging from about 18.7% to 26%.

What specific factors increase the risk for these women?

Several factors were linked to a higher risk of gestational diabetes in women with PCOS: a higher pre-pregnancy body mass index (BMI), more weight gain during pregnancy, a family history of diabetes, and higher levels of insulin resistance (HOMA-IR).

Is this study's evidence certain?

The data shows a clear link between PCOS and gestational diabetes, but the results were quite varied across different studies. Because this was an observational study rather than a clinical trial, it shows an association rather than a direct cause.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
ObjectivePolycystic ovary syndrome (PCOS), the most common endocrine disorder in reproductive-aged women, often leads to gestational diabetes mellitus (GDM). This study aimed to systematically evaluate GDM prevalence and its associated factors in PCOS.MethodsWe searched PubMed, Embase, Web of Science, Cochrane Library, CNKI, Wanfang, Sinomed, and VIP from inception to December 31, 2025. Studies reporting GDM prevalence or associated factors in PCOS were included. A random-effects model pooled prevalence with odds ratios. Egger’s test assessed publication bias, and subgroup analysis with meta-regression explored heterogeneity. A logit transformation was applied for pooling.ResultsTwenty-two studies with 5,507 PCOS patients were included. The pooled GDM prevalence was 24% (95% CI: 20%-28%; prediction interval: 10%-46%), with substantial heterogeneity (I² = 89.9%). The primary prevalence estimate, based on cohort studies (n=13), was 21.7% (95% CI: 17.7%-25.8%), while the overall estimate including case-control studies was 24% (95% CI: 20%-28%). By diagnostic criteria, GDM prevalence was 26.0% for one-step vs. 18.7% for two-step. Potentially associated factors included pre-pregnancy BMI (OR = 1.39), gestational weight gain (OR = 1.58), HOMA-IR (OR = 3.41), and family history of diabetes (OR = 2.88).ConclusionAlthough the pooled GDM prevalence in PCOS was 24%, substantial heterogeneity and a wide prediction interval (10%-46%) suggest the true prevalence varies considerably across settings. Associated factors included HOMA-IR, family history, pre-pregnancy overweight, and excessive gestational weight gain. PCOS patients should be considered a high-risk group, and early monitoring of glucose metabolism and weight management may be beneficial, though these recommendations derive from observed rather than interventional evidence.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD42026128476, identifier: CRD420261284765.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.